ARMS2 and age-related macular degeneration: Previous pharmacogenetic studies, including ours, investigated whether a single variant was associated with treatment response to exudative AMD and concluded that risk variants of ARMS2 were significantly associated with the need for additional injections and the number of additional required injections [21,22,23,24,25].